Abstract
Background The study aimed to explore the relationship between non-alcoholic fatty liver disease (NAFLD) and mortality by age and metabolic syndrome (MetS) components.
Method We enrolled 104,173 participants in the Kailuan cohort from June 2006 through October 2013. Cox regression models were used to evaluate the hazard ratio (HR) and 95% confidence interval (CI). Population-attributable fractions (PAFs) of metabolic components were also calculated.
Results Compared with non-NAFLD, the excess risk of all-cause and cardiovascular disease (CVD)-related mortality in NAFLD increased with the number of MetS components but decreased with age. The highest all-cause and CVD-related death risks were observed in NAFLD aged 18-39 with 4-5 MetS (HR=2.81, 95% CI:1.55-5.08) and those aged 40-49 years with 3 MetS (HR=2.25, 95% CI:1.55-5.08), respectively. However, there was no significant extra risk of liver-related death in NAFLD patients of any age. For PAF, 28.5% of all-cause and 43.4% of CVD-related mortality among NAFLD patients was preventable by controlling MetS components < 2, with the highest PAF in those aged 50-69 and 18-49, respectively. Elevated blood pressure (PAF of 24.7% for all-cause; 38.6% for CVD-related), elevated fasting glucose (PAF of 13.4% all-cause; 9.2% CVD-related), and elevated triglycerides (PAF of 3.9% all-cause; 14.0% CVD-related) were the essential mortality contributors in NAFLD participants.
Conclusion The excess risk of all-cause and CVD-related mortality in NAFLD patients decreases with age. A substantial proportion of risks could be averted if NAFLD patients are controlled under two MetS components, especially managing blood pressure, fasting glucose, and triglycerides for the young.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Yes, We have included details of all funding supported in the work presented
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Ethics Committees of the Kailuan General Hospital and the Institute of Basic Medical Sciences Chinese Academy of Medical Sciences approved this study. We obtained informed consent from all participants.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Abbreviations: non-alcoholic fatty liver disease (NAFLD); metabolic syndrome (MetS); cardiovascular disease (CVD); elevated blood pressure (BP); systolic blood pressure (SBP); diastolic blood pressure (DBP); elevated fasting blood glucose (FBG); triglyceride (TG); high- density lipoprotein (HDL).
